Three innovative precision medicine studies show the utility of evidence beyond that from tumor DNA sequencing to guide therapy in patients with cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology
npj Precision Oncology Open Access 26 October 2023
-
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics
Cancer and Metastasis Reviews Open Access 28 June 2023
-
Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm
Targeted Oncology Open Access 05 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Yates, L. R. Ann. Oncol. 29, 30–35 (2018).
Le, D. T. New Engl. J. Med. 372, 2509–2520 (2015).
Drilon, A. New Engl. J. Med. 378, 731–739 (2018).
Rothwell, D. G. Nat. Med. https://doi.org/10.1038/s41591-019-0380-z (2019).
Sicklick, J. K. Nat. Med. https://doi.org/10.1038/s41591-019-0407-5 (2019).
Rodon, J. Nat. Med. https://doi.org/10.1038/s41591-019-0424-4 (2019).
von Hoff, D. D. J. Clin. Oncol. 28, 4877–4883 (2010).
Stockley, T. L. Genome Med. 8, 109 (2016).
Le Tourneau, C. Lancet Oncol. 16, 1324–1334 (2015).
Belin, L. Ann. Oncol. 28, 590–596 (2017).
Massard, C. Cancer Disco. 7, 586–595 (2017).
Author information
Authors and Affiliations
Contributions
All authors contributed to the writing of the manuscript.
Corresponding author
Ethics declarations
Competing interests
C.L.T. has received consultant fees from Merck Serono, Merck & Co., Bristol-Myers Squibb, Amgen, Novartis, GlaxoSmithKline and Roche.
Rights and permissions
About this article
Cite this article
Le Tourneau, C., Borcoman, E. & Kamal, M. Molecular profiling in precision medicine oncology. Nat Med 25, 711–712 (2019). https://doi.org/10.1038/s41591-019-0442-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0442-2
This article is cited by
-
Popular deep learning algorithms for disease prediction: a review
Cluster Computing (2023)
-
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics
Cancer and Metastasis Reviews (2023)
-
NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology
npj Precision Oncology (2023)
-
Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm
Targeted Oncology (2022)
-
Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe
Insights into Imaging (2021)